Patents by Inventor David S. Perlin
David S. Perlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884985Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: GrantFiled: January 11, 2022Date of Patent: January 30, 2024Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: David S. Perlin, Steven Park, David W. Denning
-
Publication number: 20220136072Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: ApplicationFiled: January 11, 2022Publication date: May 5, 2022Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Steven Park, David W. Denning
-
Patent number: 11279936Abstract: Aptamers having a G-quadruplex structure that bind specifically to the most commonly used azole-class antifungal drugs, biosensors that comprise those aptamers, and invitro methods for determining the level of one of those drugs utilizing those aptamers or biosensors.Type: GrantFiled: August 1, 2018Date of Patent: March 22, 2022Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: David S. Perlin, Gregory R. Weidman, Yanan Zhao
-
Patent number: 11230742Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: GrantFiled: August 16, 2019Date of Patent: January 25, 2022Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: David S. Perlin, Steven Park, David W. Denning
-
Publication number: 20210277488Abstract: A detection panel for the universal detection of SARS-like coronaviruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation (“CDI”) detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer/probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.Type: ApplicationFiled: November 20, 2020Publication date: September 9, 2021Applicant: Hackensack Meridian Health, Inc.Inventors: Yanan Zhao, David S. Perlin, Steven Park
-
Patent number: 10934577Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.Type: GrantFiled: May 22, 2017Date of Patent: March 2, 2021Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, MERCK & CO., INC.Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
-
Publication number: 20200248182Abstract: Aptamers having a G-quadruplex structure that bind specifically to the most commonly used azole-class antifungal drugs, biosensors that comprise those aptamers, and invitro methods for determining the level of one of those drugs utilizing those aptamers or biosensors.Type: ApplicationFiled: August 1, 2018Publication date: August 6, 2020Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Gregory R. Weidman, Yanan Zhao
-
Publication number: 20200149119Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: ApplicationFiled: August 16, 2019Publication date: May 14, 2020Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Steven Park, David W. Denning
-
Patent number: 10385409Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: GrantFiled: May 22, 2017Date of Patent: August 20, 2019Assignee: Rutgers, the State University of New JerseyInventors: David S. Perlin, Steven Park, David W. Denning
-
Publication number: 20180256673Abstract: The disclosure relates to methods of treating a fungal infection in a subject by administering to the subject a salt of Compound 1, or a neutral form thereof. The methods of the disclosure can be useful in subjects suffering from treatment resistant infections, useful in subjects who have previously failed treatment with an anti-fungal therapy, and useful for suppressing the emergence of resistant strains in infected subjects.Type: ApplicationFiled: September 16, 2016Publication date: September 13, 2018Inventors: James Michael BALKOVEC, Kenneth BARTIZAL, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE, David S. PERLIN, Kenneth Duke JAMES, Jr.
-
Publication number: 20180002766Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: ApplicationFiled: May 22, 2017Publication date: January 4, 2018Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Steven Park, David W. Denning
-
Publication number: 20170356034Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.Type: ApplicationFiled: May 22, 2017Publication date: December 14, 2017Applicants: Rutgers, The State University of New Jersey, Merck & Co., Inc.Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
-
Patent number: 9700638Abstract: The present invention provides compounds useful as novel near-infrared labels, compositions containing these compounds, and methods of using the near-infrared labels to identify targets in vitro, in situ and in vivo. The invention also provides small or large molecule conjugates between targeting agents and NIR labels, as well as methods and kits thereof, that can be used in diagnostics and treatment of diseases related to microbes in mammalian animals.Type: GrantFiled: May 8, 2014Date of Patent: July 11, 2017Assignees: Rutgers, The State University of New Jersey, New Jersey Institute of TechnologyInventors: Arkady Mustaev, David S. Perlin, Laura Wirpsza
-
Patent number: 9657355Abstract: Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera Candida, Aspergillus and Pneumocystis. The methods include obtaining a sample suspected of containing fungal nucleic acid, including at least one universal region of fungal nucleic acid, and testing for the presence or absence in the sample of the at least one universal region of fungal nucleic acid. Samples may be biological or non-biological.Type: GrantFiled: November 1, 2007Date of Patent: May 23, 2017Assignee: Rutgers, the State University of New JerseyInventors: Steven Park, David S. Perlin, David Wemyss Denning
-
Patent number: 9657334Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.Type: GrantFiled: June 16, 2014Date of Patent: May 23, 2017Assignees: Rutgers, The State University of New Jersey, Merck & Co., Inc.Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
-
Publication number: 20160106867Abstract: The present invention provides compounds useful as novel near-infrared labels, compositions containing these compounds, and methods of using the near-infrared labels to identify targets in vitro, in situ and in vivo. The invention also provides small or large molecule conjugates between targeting agents and NIR labels, as well as methods and kits thereof, that can be used in diagnostics and treatment of diseases related to microbes in mammalian animals.Type: ApplicationFiled: May 8, 2014Publication date: April 21, 2016Applicants: Rutgers, The State University of New Jersey, New Jersey Institute of TechnologyInventors: Arkady Mustaev, David S. Perlin, Laura Wirpsza
-
Publication number: 20150125856Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.Type: ApplicationFiled: June 16, 2014Publication date: May 7, 2015Inventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer N. Kahn, Stephen A. Parent, Rosemarie Kelly
-
Publication number: 20150098905Abstract: The present invention relates to targeting agents and methods: of using the targeting agents to detect a fungal cell in a subject.Type: ApplicationFiled: May 8, 2013Publication date: April 9, 2015Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Guillermo Garcia-Effron, Arkady Mustaev
-
Patent number: 8753819Abstract: Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays.Type: GrantFiled: July 26, 2006Date of Patent: June 17, 2014Assignee: Rutgers, The State University of New JerseyInventors: David S. Perlin, Steven Park, Cameron M. Douglas, Jennifer Nielsen Kahn, Stephen A. Parent, Rosemarie Kelly
-
Publication number: 20110091872Abstract: Methods are provided for detecting triazole -resistant fungi in a sample. The methods comprise evaluating the sample for the presence of a gene encoding a mutant AzRF1 transcription factor, or the level of the transcription factor, to determine whether a fungus is triazole-resistant. Primers, probes and kits also are provided.Type: ApplicationFiled: May 2, 2008Publication date: April 21, 2011Inventors: Eleusa Maria F. Rocha, Steven Park, David S. Perlin